Ramucirumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | VEGFR2 (KDR) |
| Clinical data | |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 947687-13-0  |
| ATC code | None |
| UNII | D99YVK4L0X  |
| Chemical data | |
| Formula | C6374H9864N1692O1996S46 |
| Mol. mass | 143.6 kDa |
| (what is this?) (verify) | |
Ramucirumab (IMC-1121B)[1] is a fully human monoclonal antibody (IgG1) being developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.
Ramucirumab is being tested in several phase III clinical trials for the treatment of metastatic gastric adenocarcinoma,[2] non-small cell lung cancer,[3] among other types of cancer. On September 26, 2013 Eli Lilly announced that its Phase III study for ramucirumab failed to hit its primary endpoint on progression-free survival among women with metastatic breast cancer.[4][5]
This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab, American Medical Association.
- ↑ ClinicalTrials.gov NCT01170663 A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma (RAINBOW)
- ↑ ClinicalTrials.gov NCT01168973 A Study in Second Line Non Small Cell Lung Cancer
- ↑ ClinicalTrials.gov NCT00703326 Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
- ↑ Fierce Biotech. "In another stinging setback, Eli Lilly's ramucirumab fails PhIII breast cancer study". Retrieved 27 September 2013.
| |||||||||||||||||||||||||||||||||||||||||||||